The Conversation (0)
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in November:
Guggenheim Securities Healthcare Innovation Conference
Presentation Date: Tuesday, November 11, 2025 at 9:00 AM ET
Presentation Format: Fireside Chat
Webcast: Here
Stifel 2025 Healthcare Conference
Presentation Date: Wednesday, November 12, 2025 at 8:40 AM ET
Presentation Format: Fireside Chat
Webcast: Here
Jefferies London Healthcare Conference
Presentation Date: Tuesday, November 18, 2025 at 5:00 PM GMT
Presentation Format: Presentation
Webcast: Here
Replays of the events will be available in the Investors section on the Company's website at www.soleno.life .
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's first commercial product, VYKAT XR™ (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life .
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
